Current Takeaway
Vagus and tragus nerve stimulation involves modulating the autonomic nervous system using non-invasive transcutaneous auricular devices (taVNS/LL-TS) or percutaneous approaches. By targeting the auricular branch of the vagus nerve, these interventions aim to restore parasympathetic activity and suppress sympathetic over-activation to address dysautonomia and post-viral fatigue.
Clinical trials have yielded mixed results. Although low-level tragus stimulation has demonstrated sustained physiological and symptomatic benefits in post-COVID Postural Orthostatic Tachycardia Syndrome (POTS), larger studies on post-COVID fatigue show conflicting evidence, with one trial showing significant fatigue reduction in adherent participants and another pilot trial showing no benefit over sham treatment.
Because of small sample sizes, variable device adherence, and strong potential placebo effects, the clinical efficacy of vagus nerve stimulation for post-viral fatigue and orthostatic syndromes remains early and unestablished. Objective biological markers and larger sham-controlled cohorts are needed to confirm the therapeutic benefit.
Why This Matters
Targeting the vagus nerve addresses a suspected core mechanism of post-viral syndromes: autonomic nervous system dysregulation and systemic inflammation. Because non-invasive ear-clip devices are relatively safe, affordable, and feasible for home use, demonstrating clear clinical efficacy would establish a highly scalable, non-pharmacological treatment option. Conversely, rigorous sham-controlled trials are critical to distinguish actual neuromodulation effects from the strong placebo responses and natural recovery patterns common in fatigue and dysautonomia research.
State of Evidence
- Established: Low-level tragus stimulation (LL-TS) significantly reduces orthostatic heart rate acceleration and lowers plasma neuropeptide Y (NPY) in patients with post-COVID POTS.
- Plausible but early: Daily transcutaneous auricular vagus nerve stimulation (taVNS) may improve subjective fatigue, peripheral muscle fatigue, and cortical excitability in patients who adhere to at least one hour of daily stimulation.
- Not established: Clear superiority of active taVNS over sham stimulation for fatigue reduction in general post-COVID populations has not been demonstrated, with pilot trials showing similar improvements in sham groups.
- Key limitations: Existing studies are constrained by small sample sizes (under 120 participants), high rates of participant non-adherence in home-based protocols, short trial durations, and a lack of double-blinded designs that could rule out strong placebo responses.
Timeline
2025-02-19 - Low-level tragus stimulation trial for post-COVID POTS published
A randomized, sham-controlled trial (57 participants) evaluated low-level tragus stimulation (LL-TS) using an ear clip device for post-COVID Postural Orthostatic Tachycardia Syndrome (POTS). Patients received either active LL-TS or sham stimulation for one hour twice daily over one month, showing a significant and sustained reduction in standing heart rate at a one-year follow-up. This active treatment also normalized autonomic balance as measured by heart rate variability (HRV) and significantly lowered plasma levels of neuropeptide Y (NPY), a marker of sympathetic activity. While these physiological changes point to parasympathetic activation as a viable therapeutic mechanism, the study did not assess broader clinical POTS symptoms like cognitive impairment or fatigue. Furthermore, the lack of a healthy control group or non-POTS Long COVID control group makes it difficult to verify if these effects are specific to POTS.
Sources:
2026-01-02 - Home-based auricular nerve stimulation preprint shows fatigue reduction in adherent participants
A randomized, single-blinded crossover trial (PAuSing-pCF) involving 114 participants evaluated 16 weeks of daily home-based transcutaneous auricular vagus nerve stimulation (taVNS) for post-COVID fatigue. Active stimulation at the tragus led to a significant 11.9-point improvement in subjective fatigue scores compared to the control group, but only among participants who adhered to the protocol for at least one hour daily. The active intervention also led to objective improvements in peripheral muscle fatigue, normalized autonomic function, and normalized cortical excitability. These findings connect subjective fatigue improvements with objective physiological markers, supporting autonomic and motor system regulation as central mechanisms. However, because this work was released as a preprint, it has not yet undergone official peer review to validate the results. The high rate of non-adherence also limits the strength of the evidence, as the primary efficacy was restricted to a compliant subset which may introduce selection bias.
Sources:
2026-04-02 - COVIVA pilot trial reports no significant benefit of taVNS over sham stimulation
The randomized, single-blinded COVIVA pilot trial (45 participants) investigated the efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for Long COVID fatigue. Participants used a CE-certified device for four hours daily over four weeks, achieving high device compliance. Although fatigue and quality of life scores improved for all participants, active stimulation (sub-threshold or above-threshold) did not show any statistically significant difference compared to sham stimulation. This result indicates a strong potential for placebo effects or natural symptom recovery during the trial period. It does not rule out taVNS efficacy entirely, as the small sample size and short four-week duration may have been insufficient to detect a true therapeutic effect. However, it underlines that active electrical stimulation is not yet proven superior to placebo for fatigue, and highlights the need for rigorous, double-blinded designs with objective biological markers.
Sources:
2026-06-18 - Clinical trial protocol published to evaluate combined auricular vagal neuromodulation and slow-paced breathing in POTS
A randomised controlled trial protocol published in BMJ Open by Brandl et al. outlines the design of a single-centre, partially blinded, 2×2 factorial trial at the Medical University of Vienna (NCT06996314). The study aims to evaluate the combined and individual effects of daily 60-minute auricular vagal neuromodulation therapy (AVNT) and daily 10–15 minutes of slow-paced diaphragmatic breathing (SDB) in 100 individuals with POTS (including those with Long COVID or stable mild PEM). As a trial protocol, this publication describes study design and does not report clinical efficacy data; findings are subject to completion of the trial. The primary outcome is the change in orthostatic heart rate during a standardized 70° head-up tilt test, with secondary outcomes measuring autonomic responses, handgrip strength, and patient-reported symptoms.
Sources: